751 reports of this reaction
2.1% of all DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE reports
#8 most reported adverse reaction
DEHYDRATION is the #8 most commonly reported adverse reaction for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 751 FDA adverse event reports linking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE to DEHYDRATION. This represents approximately 2.1% of all 35,651 adverse event reports for this drug.
Patients taking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE who experience dehydration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEHYDRATION is a less commonly reported adverse event for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, but still significant enough to appear in the safety profile.
In addition to dehydration, the following adverse reactions have been reported for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE:
The following drugs have also been linked to dehydration in FDA adverse event reports:
DEHYDRATION has been reported as an adverse event in 751 FDA reports for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEHYDRATION accounts for approximately 2.1% of all adverse event reports for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, making it a notable side effect.
If you experience dehydration while taking DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.